Tech Company Financing Transactions
Ariceum Therapeutics Funding Round
Ariceum Therapeutics, based in Berlin, received $26 million in investment from Healthcap Venture Capital, LSP BioVentures and Pureos Bioventures.
Transaction Overview
Company Name
Announced On
6/13/2022
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to further develop its lead asset and proprietary peptide derivative, satoreotide.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Robert-Rössle-Straße. 10 Building 79
Berlin, 13125
Germany
Berlin, 13125
Germany
Phone
Undisclosed
Website
Email Address
Overview
Ariceum Therapeutics is developing novel drugs for systemic targeted radiotherapy (STR); Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Manfred Rüdiger
Chief Medical Officer
Alexander McEwan
Vice President
Ben Pais
VP - Operations
Tom Halliwell
VP - Operations
Claudio Pediconi
Browse more venture capital transactions:
Prev: 6/13/2022: Terra.do venture capital transaction
Next: 6/13/2022: GeniusX venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs